0RV2.LSE

BioArctic AB Series B

0RV2.LSE, UK

BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical needs. The company's therapeutic areas encompass neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease, and other CNS diseases. In addition, it owns a technology platform, which develops a range of therapeutic monoclonal antibodies. Additionally, the company is developing lecanemab, which is in phase 3 clinical trials; Lecanemab that is in back-up phase 3 clinical trials; Exidavnemab, which is in phase 2 clinical trials; Lecanemab, BAN2803, and BAN2802 that are in preclinical trials; and BAN1503, PD-BT2238, ND-BT3814, and GD-BT6822, which are in discovery stage. It has research collaboration agreements with Eisai and AbbVie. The company was formerly known as BioArctic Neuroscience AB and changed its name to BioArctic AB (publ) in 2016. BioArctic AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.

https://www.bioarctic.se

Stock Price

SEK0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A

Finn Analysis

(Last Updated 2023-06-30)

Health Score

Investors

* Institutions hold a combined 0.00% of the total shares of BioArctic AB Series B

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

-0.43

Latest Release

Date

2025-09-30

EPS Actual

-0.9807

EPS Estimate

-1.06

EPS Difference

0.0793

Surprise Percent

7.4811%

Investing Fit Scorecard

(Last Updated 2023-06-30)

Deep Value
Weak Deep Value(0)
Defensive
Moderately Defensive(5)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
No Clear Moat(1)
GARP
Not Attractive for GARP(0)
Growth
Weak Growth Prospect(0)
Momentum
No Momentum(2)
Net Net
Not Undervalued (Net-Net)(0)
Quality
Low Quality Business(0)
Value
Overpriced(1.5)

Income Statement

(Last Updated 2023-06-30)

Revenue

SEK 0

Cost Of Revenue

SEK 0

Gross Profit

SEK 0

Operating Expenses

SEK 0

Operating Income

SEK 0

Interest Expense

SEK 0

Pretax Income

SEK 0

Net Income

SEK 0

Income Tax Expense

SEK 0

EBITDA

SEK 0

Total Other Income Expense Net

SEK 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2023-06-30)

Cash

SEK 0

Short Term Investments

SEK 0

Receivables

SEK 0

Inventories

SEK 0

Total Current Assets

SEK 0

Property Plant Equipment

SEK 0

Total Assets

SEK 0

Payables

SEK 0

Short Term Debt

SEK 0

Long Term Debt

SEK 0

Total Liabilities

SEK 0

Equity

SEK 0

Trend

Cash Flow

(Last Updated 2023-06-30)

Net Income

SEK 0

Depreciation

SEK 0

Change In Working Capital

SEK 0

Cash From Operations

SEK 0

Capital Expenditures

SEK 0

Cash From Investing

SEK 0

Cash From Financing

SEK 0

Net Change In Cash

SEK 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.